KemPharm Inc. (NASDAQ:KMPH) rose 2.8% on Thursday . The company traded as high as $4.55 and last traded at $4.44, with a volume of 56,591 shares changing hands. The stock had previously closed at $4.32.

KMPH has been the topic of a number of research analyst reports. Oppenheimer Holdings Inc. restated a “buy” rating on shares of KemPharm in a research note on Wednesday, June 8th. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Tuesday, August 16th. Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a research report on Wednesday, August 10th. Finally, Royal Bank Of Canada cut their target price on shares of KemPharm from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, May 6th.

The company has a 50 day moving average of $4.39 and a 200-day moving average of $9.56. The firm’s market cap is $65.03 million.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.94) by $0.36. Analysts predict that KemPharm Inc. will post ($1.72) earnings per share for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.